Cardinal Health, Inc. — Q2 FY2024 Form 10-Q
Reporting period: Quarter and six months ended December 31, 2023; fiscal year ends June 30. Comparisons are with the corresponding prior-year periods unless noted.
Business context and results
Cardinal Health is a healthcare services and products company operating through Pharmaceutical and Medical segments. Revenue growth was primarily driven by branded and specialty pharmaceutical sales to existing customers.
| Metric | Q2 FY2024 | Six months FY2024 |
|---|---|---|
| Revenue | $57.4 billion, up 12% | $112.2 billion, up 11% |
| GAAP operating earnings | $482 million; prior-year loss of $119 million | $468 million; prior-year earnings of $18 million |
| Non-GAAP operating earnings | $562 million, up 20% | $1.133 billion, up 27% |
| GAAP diluted EPS | $1.43; prior-year loss of $0.50 | $1.44; prior-year loss of $0.08 |
| Non-GAAP diluted EPS | $1.82, up 38% | $3.55, up 41% |
| Gross margin | $1.846 billion, up 11% | $3.614 billion, up 10% |
Q2 segment profit was $518 million for Pharmaceutical, up 12%, and $71 million for Medical, versus $17 million a year earlier. Six-month segment profit was $1.025 billion and $142 million, respectively. Corporate costs were $107 million in Q2 and $699 million for the six months.
Cash flow, liquidity and capital
Six-month operating cash flow was $1.734 billion, compared with $620 million in the prior-year period. It included a $378 million opioid settlement payment. Working-capital movements included a $2.536 billion inventory increase and a $4.446 billion increase in accounts payable.
Cash and equivalents were $4.591 billion at December 31, 2023, versus $4.043 billion at June 30, 2023. Total long-term obligations, including current amounts and other short-term borrowings, were $4.7 billion at both dates. No amounts were outstanding under the $2.0 billion commercial paper/revolving credit arrangements or the $1.0 billion receivables facility; the company was in compliance with its 3.75-to-1 net leverage covenant.
During the six months, the company spent $750 million on share repurchases, $255 million on dividends and $206 million on capital expenditures. The balance sheet reported a shareholders’ deficit of $3.447 billion.
Material changes and unusual items
- A $581 million non-cash pre-tax goodwill impairment was recorded for the Medical Unit in the first fiscal quarter. Prior-year impairment charges were $709 million in Q2 and $863 million for the six months. The impairment was driven primarily by a higher discount rate.
- Prior-year comparisons also included litigation recoveries; current-period litigation items included a $22 million charge related to an agreement in principle with Alabama and antitrust recoveries.
- Gross margin rate declined 2 basis points in both the quarter and six-month period. Higher branded pharmaceutical distribution sales increased revenue but diluted the overall margin rate; Medical inflation comparisons, generics performance and branded/specialty contributions supported gross margin.
- Effective January 1, 2024, Cardinal Health reorganized reporting into Pharmaceutical and Specialty Solutions, Global Medical Products and Distribution, and Other. The filing’s reported results use the prior segment structure.
Outlook, risks and contingencies
- The filing provides no specific numerical full-year earnings or revenue guidance. Management said COVID-19 vaccine distribution’s future volume and profit contribution are uncertain; generics performance depends on volumes, pricing, contract renewals and sourcing costs.
- Management expects Medical inflationary impacts to continue through the rest of FY2024, but at a significantly lesser extent than in FY2023 and prior periods. Costs and mitigation outcomes remain uncertain.
- Goodwill reallocation following the segment change may lead to additional impairment testing and potential charges. Management cautioned that adverse changes in assumptions or business conditions could further reduce fair value. A hypothetical 0.5 percentage-point increase in the discount rate would have reduced Medical Unit fair value by about $450 million; a 25-basis-point decline in long-term gross margin rates by about $300 million.
- At December 31, 2023, the company had accrued $5.47 billion for opioid matters and expects most remaining payments through 2038. In January 2024, it prepaid about $238 million of future settlement amounts, expecting approximately $100 million of litigation recovery income in the quarter ending March 31, 2024. Private opioid claims and government investigations remain ongoing; the company said it cannot estimate a range of reasonably possible additional losses.
- On January 31, 2024, Cardinal Health agreed to acquire Specialty Networks for $1.2 billion in cash, subject to adjustments and customary closing conditions, including regulatory approval. It plans to use available cash. The filing identifies liquidity, integration, retention, regulatory and expected-benefit risks.
- Management stated that available capital resources and projected operating cash flow are expected to fund operations and anticipated needs. Additional acquisitions could require capital-market financing.
Most important facts for investors to verify
- Whether growth in pharmaceutical distribution and specialty products translates into sustained segment profit, given the dilutive mix effect on gross margin rate.
- Medical segment performance and whether assumptions underlying goodwill valuations remain supportable after the reporting-structure change.
- Actual cash requirements and any changes to the $5.47 billion opioid accrual, future settlement payments or private-claim exposure.
- Completion, funding and integration of the Specialty Networks acquisition, and its effect on cash, liquidity and returns.
- Non-GAAP reconciliations and exclusions: non-GAAP results exclude items including impairment, restructuring and litigation; they supplement, but do not replace, GAAP results.